2026· Methods in Enzymology· Vol 733, pp.
163-222
· 0 citations
Medicine
TL;DR
Overall, epigenetic modulators present a promising therapeutic approach for neurodegeneration, and continued research integrating various assays like DNA methylation analysis, histone modification analysis, non-coding RNA analysis, neuroinflammation analysis, and functional and behavioral assays in AD models is significant in harnessing the full potential for AD treatment.
The chapter provides in-depth information on the role of HDAC inhibitors, which hold significant potential as disease-modifying agents in the treatment of Alzheimer's disease and explores various challenges such as off-target effects, restricted isoform specificity, and inadequate blood-brain barrier permeability.
Vedika Jain, S. Bharti· International review of neur...· 0 citations
Pharmacological inhibition of HDAC activity has been shown to restore histone acetylation levels, enhance the expression of neuroprotective genes, and improve synaptic plasticity in various experimental models.
Padmanabh Singh, M. K. Thakur· Methods in Enzymology· 0 citations
A deeper understanding of aging-associated molecular dysfunction is essential to design sustainable, disease-modifying therapeutics with cross-disease relevance.
Nagaraj Rangappa, Riddhi Upadhyay, Nathish Lakshman et al.· Advances in Protein Chemistr...· 0 citations
Targeting the biochemical modulators of synaptic plasticity offers a promising avenue for AD therapy, especially through combinatorial and precision-medicine strategies aimed at restoring synaptic function and cognitive performance.
I. Farzeen, Muhammad Muzammil Nazir, Zunaira Jaan et al.· Journal of Alzheimer's Disea...· 0 citations
Neurodegenerative diseases are a heterogeneous group of chronic and progressive disorders, which are characterized by selective neuronal destruction, synaptic malfunction and progressive cognitive and locomotor dysfunction. The major ones are Alzheimer disease, Parkinson disease, Huntington disease, and amyotrophic lat...
Nisha, Sumairah Qadir· Current Pharmaceutical Resea...· 0 citations
Current insights into the roles of miRNAs, lncRNAs, and chromatin modifiers in Parkinson’s disease are critically summarized, their potential as biomarkers and therapeutic targets are discussed, and key challenges and future perspectives in translating epigenetic discoveries into clinical applications are highlighted.
Sumithira George, Sivakumar Subramaniyan, Mukesh Rajagopal et al.· Scholars Journal of Applied...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
